Leerink Partnrs Issues Optimistic Outlook for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Leerink Partnrs raised their Q4 2025 earnings estimates for Bristol Myers Squibb in a note issued to investors on Thursday, October 30th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $1.65 per share for the quarter, up from their prior forecast of $1.62. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb’s FY2026 earnings at $5.89 EPS and FY2027 earnings at $5.98 EPS.

A number of other equities analysts have also commented on BMY. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research note on Tuesday, August 5th. Finally, Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have assigned a Hold rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Stock Up 1.0%

NYSE BMY opened at $46.10 on Monday. The stock’s 50 day simple moving average is $45.34 and its 200 day simple moving average is $46.78. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $63.33. The firm has a market cap of $93.82 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter last year, the business posted $1.80 earnings per share. The company’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.4%. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. New England Asset Management Inc. grew its position in Bristol Myers Squibb by 0.8% during the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company’s stock valued at $2,408,000 after acquiring an additional 305 shares during the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Bristol Myers Squibb by 1.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company’s stock worth $78,580,000 after acquiring an additional 13,959 shares during the last quarter. Sage Capital Advisors llc boosted its stake in shares of Bristol Myers Squibb by 60.7% in the 2nd quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company’s stock valued at $3,946,000 after purchasing an additional 32,181 shares in the last quarter. Castle Rock Wealth Management LLC grew its holdings in shares of Bristol Myers Squibb by 458.2% during the 2nd quarter. Castle Rock Wealth Management LLC now owns 44,559 shares of the biopharmaceutical company’s stock valued at $2,088,000 after purchasing an additional 36,576 shares during the last quarter. Finally, Advocate Group LLC raised its position in Bristol Myers Squibb by 4.8% in the 2nd quarter. Advocate Group LLC now owns 154,239 shares of the biopharmaceutical company’s stock worth $7,140,000 after purchasing an additional 7,088 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.